FDA appears to have added a post-marketing commitment for its approval of Prevnar 13 for adults age 50 and older as a result of advisory committee concerns about the immunogenicity data.
Pfizer Inc.’sconjugate vaccine was approved Dec. 30 to prevent pneumonia and invasive disease caused by streptococcus pneumoniae bacteria serotypes...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?